Full Press Release Details
("Midatech" or the "Company")
MTD201 Development Plan
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce
that it has finalised the development plan for its key MTD201 Q-Octreotide product, a treatment for acromegaly and neuroendocrine
tumours (NET) based on the Company's unique polymer microsphere technology, Q-Sphera for sustained drug delivery.
Following consultations with key opinion
leaders, regulators, and potential partners, the Company plans to develop MTD201 as a new differentiated product for the treatment
of acromegaly and NETs. Midatech has determined that the product characteristics uniquely conferred by Q-Sphera support this positioning
of MTD201 to provide the most valuable, de-risked development programme for the Company. A key factor underpinning this decision
is the significant competitive advantage and value added as a result of Midatech's Q-Sphera sustained release technology.
The technology has patent protection into the 2030's.
As previously reported, the pharmacokinetic
and pharmacodynamic profile of MTD201 established in Midatech's 2018 Phase I exploratory study versus market leading Novartis'
Sandostatin LAR (SLAR) delivered favourably on the target profile requirements needed compared to current marketed long-acting
somatostatin analogues. Additional advantages demonstrated in the study include smaller, less painful needle size, simpler and
error free reconstitution and injection, quicker bedside reconstitution (taking less than 10 minutes versus up to 40 minutes for
SLAR), reduced wastage and significantly lower manufacturing costs.
Midatech expects further competitive advantages
to be leveraged in a differentiated MTD201 product versus other players in the market, such as SLAR, to be:
The next phase of clinical development
for MTD201 as a differentiated product is scheduled to commence in H2 2019 to support a first indication in acromegaly. The pivotal
registration study in acromegaly patients will seek to compare MTD201 versus placebo and is planned to commence early 2020 following
receipt of approval by regulators. Prior to this, Midatech plans a short Phase I study to look to confirm the use of the sub-cutaneous
route in the pivotal trial, which the Company believes will provide further significant advantages, as outlined above. The pivotal
program, the costs of which are expected to be in-line with the previously stated budget expectations as outlined on 4 February
2019, is expected to conclude in 2021 and, subject to a successful outcome and expected completion on commercial scale-up of MTD201
production at the Company's manufacturing facility in Bilbao, Midatech plans to submit marketing authorisation applications
the same year. Subject to funding, a pivotal registration programme to support a second indication in NET is expected to commence
Commenting, Midatech's Chief Executive
Officer, Dr Craig Cook, said: " We are delighted to be able to lay out our roadmap to bring MTD201 to market. Building
on the exciting Phase I data and further leveraging the full potential of the Q-Sphera differentiating technology promises a compelling
product opportunity for MTD201. The development path has been finalised in close collaboration with our distinguished advisory
board, and we believe we have a clear path to potential commercialisation. We look forward to providing regular updates as the
development programme progresses."
For more information, please contact:
(UK) Limited (Nominated Adviser and Broker)
Emma Earl (Corporate Finance)
Limited (Financial PR and UK Investor Relations)
/ Tim Metcalfe / Heather Armstrong
Westwicke Partners (US Investor Relations)
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Pharma (LSE AIM: MTPH; NASDAQ: MTP) is an R&D company focused on delivering innovative oncology and rare disease products to
patients. The Company is developing a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary
platform drug delivery technologies, all of which are in the clinic, specifically:
of our three technologies are thus focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the
body where they are needed and can exert their actions in an effective, safe and precise manner.
headquarters and R&D facility is in Cardiff, UK, with a manufacturing operation in Bilbao, Spain. For more information please
visit www.midatechpharma.com
statements in this announcement may constitute "forward-looking statements" within the meaning of legislation in the
United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements expressed or implied
regarding our plans, goals, and milestones, our ability to successfully test, manufacture, produce or commercialise products for
conditions using our drug delivery platforms, the ability for products in development, including MTD201, to achieve positive clinical
results, the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions
and the associated costs of such studies, trials or submissions, and other economic, business and/or competitive factors. The risks
included are not exhaustive. Any forward-looking statements are based on currently available competitive, financial and economic
data together with management's views and assumptions regarding future events and business performance as of the time the statements
are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that
could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such
forward-looking statements.
should be made to those documents that we shall file from time to time or announcements that may be made by the Company in accordance
with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs")
and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important
factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.
These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking
statements by or concerning the Company are expressly qualified in their entirety by the cautionary statements above. Except as
may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, we do not undertake
any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise